Business Context and Reporting Period
This Form 8-K is filed by Sunshine Heart, Inc. (not Nuwellis, Inc.) on June 26, 2015. The report details the funding of a milestone-based term loan under a previously disclosed agreement with Silicon Valley Bank.
Key Financial Metrics
- Debt Financing: The Company borrowed an additional $2.0 million (Term B Loan) on June 26, 2015.
- Commitment Fee: A fee of 1% of the Term B Loan ($20,000) was paid to the Bank.
- Total Facility: The aggregate principal amount of the loan facility is up to $10.0 million, consisting of a $6.0 million initial term loan, the $2.0 million Term B Loan, and a potential $2.0 million Term C Loan.
- Liquidity Requirement: The Company must complete an equity financing resulting in unencumbered net cash proceeds of at least $20.0 million by March 31, 2016.
- Equity Issuance: Warrants previously issued to the Bank became exercisable for additional shares equal to 6% of the Term B Loan amount divided by the Funding Shares Warrant Price.
Material Changes
The primary material change is the achievement of the regulatory milestone required to access the Term B Loan. The U.S. Food and Drug Administration granted an interim analysis of the Company's "C-Pulse Heart Assist System" product in February 2015, triggering the availability of the $2.0 million funding which was executed on June 26, 2015.
Outlook, Risks, and Contingencies
- Future Financing Obligation: The Company is contractually obligated to raise at least $20.0 million in equity by March 31, 2016, to maintain the loan terms.
- Dilution Risk: The funding of the Term B Loan triggered the exercisability of additional warrants, potentially diluting existing shareholders.
- Unregistered Securities: The warrants and underlying shares were issued under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D and are not registered with the SEC.
- Remaining Milestone: An additional $2.0 million term loan remains available if the Company enrolls 100 patients in the "U.S. Counter HF" study by September 30, 2015.
Investor Verification Checklist
- Verify the Company's progress toward the $20.0 million equity financing deadline of March 31, 2016.
- Confirm the status of patient enrollment for the "U.S. Counter HF" study to determine eligibility for the remaining $2.0 million loan tranche.
- Review the impact of the newly exercisable warrants on the Company's capital structure and potential dilution.
- Check for any subsequent filings regarding the equity financing efforts required by the loan agreement.